521 related articles for article (PubMed ID: 19660879)
1. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study.
Zhang X; Li Y; Pan X; Xiaoqiang L; Mohan R; Komaki R; Cox JD; Chang JY
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):357-66. PubMed ID: 19660879
[TBL] [Abstract][Full Text] [Related]
2. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer.
Register SP; Zhang X; Mohan R; Chang JY
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1015-22. PubMed ID: 20615629
[TBL] [Abstract][Full Text] [Related]
3. An in-silico comparison of proton beam and IMRT for postoperative radiotherapy in completely resected stage IIIA non-small cell lung cancer.
Berman AT; Teo BK; Dolney D; Swisher-McClure S; Shahnazi K; Both S; Rengan R
Radiat Oncol; 2013 Jun; 8():144. PubMed ID: 23767810
[TBL] [Abstract][Full Text] [Related]
4. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer.
Chang JY; Zhang X; Wang X; Kang Y; Riley B; Bilton S; Mohan R; Komaki R; Cox JD
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1087-96. PubMed ID: 16682145
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169
[TBL] [Abstract][Full Text] [Related]
6. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study.
Welsh J; Gomez D; Palmer MB; Riley BA; Mayankkumar AV; Komaki R; Dong L; Zhu XR; Likhacheva A; Liao Z; Hofstetter WL; Ajani JA; Cox JD
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1336-42. PubMed ID: 21470796
[TBL] [Abstract][Full Text] [Related]
7. Clinical implementation of intensity modulated proton therapy for thoracic malignancies.
Chang JY; Li H; Zhu XR; Liao Z; Zhao L; Liu A; Li Y; Sahoo N; Poenisch F; Gomez DR; Wu R; Gillin M; Zhang X
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):809-18. PubMed ID: 25260491
[TBL] [Abstract][Full Text] [Related]
8. Intensity-modulated radiotherapy for locally advanced non-small-cell lung cancer: a dose-escalation planning study.
Lievens Y; Nulens A; Gaber MA; Defraene G; De Wever W; Stroobants S; Van den Heuvel F;
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):306-13. PubMed ID: 20888706
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer.
Liu HH; Wang X; Dong L; Wu Q; Liao Z; Stevens CW; Guerrero TM; Komaki R; Cox JD; Mohan R
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1268-79. PubMed ID: 15001272
[TBL] [Abstract][Full Text] [Related]
10. Dosimetric comparison of combined intensity-modulated radiotherapy (IMRT) and proton therapy versus IMRT alone for pelvic and para-aortic radiotherapy in gynecologic malignancies.
Milby AB; Both S; Ingram M; Lin LL
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e477-84. PubMed ID: 22177626
[TBL] [Abstract][Full Text] [Related]
11. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.
Liao Z; Lee JJ; Komaki R; Gomez DR; O'Reilly MS; Fossella FV; Blumenschein GR; Heymach JV; Vaporciyan AA; Swisher SG; Allen PK; Choi NC; DeLaney TF; Hahn SM; Cox JD; Lu CS; Mohan R
J Clin Oncol; 2018 Jun; 36(18):1813-1822. PubMed ID: 29293386
[TBL] [Abstract][Full Text] [Related]
12. Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC.
Gjyshi O; Xu T; Elhammali A; Boyce-Fappiano D; Chun SG; Gandhi S; Lee P; Chen AB; Lin SH; Chang JY; Tsao A; Gay CM; Zhu XR; Zhang X; Heymach JV; Fossella FV; Lu C; Nguyen QN; Liao Z
J Thorac Oncol; 2021 Feb; 16(2):269-277. PubMed ID: 33198942
[TBL] [Abstract][Full Text] [Related]
13. Effects of respiratory motion on passively scattered proton therapy versus intensity modulated photon therapy for stage III lung cancer: are proton plans more sensitive to breathing motion?
Matney J; Park PC; Bluett J; Chen YP; Liu W; Court LE; Liao Z; Li H; Mohan R
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):576-82. PubMed ID: 24074932
[TBL] [Abstract][Full Text] [Related]
14. Proton arc reduces range uncertainty effects and improves conformality compared with photon volumetric modulated arc therapy in stereotactic body radiation therapy for non-small cell lung cancer.
Seco J; Gu G; Marcelos T; Kooy H; Willers H
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):188-94. PubMed ID: 23920395
[TBL] [Abstract][Full Text] [Related]
15. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer.
Schwarz M; Alber M; Lebesque JV; Mijnheer BJ; Damen EM
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):561-70. PubMed ID: 15890601
[TBL] [Abstract][Full Text] [Related]
16. Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC.
Giaddui T; Chen W; Yu J; Lin L; Simone CB; Yuan L; Gong YU; Wu QJ; Mohan R; Zhang X; Bluett JB; Gillin M; Moore K; O'Meara E; Presley J; Bradley JD; Liao Z; Galvin J; Xiao Y
Radiat Oncol; 2016 May; 11():66. PubMed ID: 27142674
[TBL] [Abstract][Full Text] [Related]
17. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.
Grills IS; Yan D; Martinez AA; Vicini FA; Wong JW; Kestin LL
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):875-90. PubMed ID: 14529795
[TBL] [Abstract][Full Text] [Related]
18. The feasibility of dose escalation using intensity-modulated radiotherapy (IMRT) and intensity-modulated proton therapy (IMPT) with FDG PET/CT guided in esophageal cancer.
Zhang Y; Fan B; Sun T; Xu J; Yin Y; Chen Z; Zhu J; Yu J; Hu M
J Cancer Res Ther; 2022 Sep; 18(5):1261-1267. PubMed ID: 36204871
[TBL] [Abstract][Full Text] [Related]
19. Small-spot intensity-modulated proton therapy and volumetric-modulated arc therapies for patients with locally advanced non-small-cell lung cancer: A dosimetric comparative study.
Liu C; Sio TT; Deng W; Shan J; Daniels TB; Rule WG; Lara PR; Korte SM; Shen J; Ding X; Schild SE; Bues M; Liu W
J Appl Clin Med Phys; 2018 Nov; 19(6):140-148. PubMed ID: 30328674
[TBL] [Abstract][Full Text] [Related]
20. Organ sparing potential and inter-fraction robustness of adaptive intensity modulated proton therapy for lung cancer.
van der Laan HP; Anakotta RM; Korevaar EW; Dieters M; Ubbels JF; Wijsman R; Sijtsema NM; Both S; Langendijk JA; Muijs CT; Knopf AC
Acta Oncol; 2019 Dec; 58(12):1775-1782. PubMed ID: 31556764
[No Abstract] [Full Text] [Related]
[Next] [New Search]
